Xeris Biopharma Holdings, Inc. (XERS) Form 8-K — Nov 2, 2026
Xeris Biopharma appointed Menassie M. Taddese to its Board of Directors effective November 2, 2026, expanding the board from eight to nine members. He joins the Audit Committee as a Class II director with a term expiring at the 2029 annual meeting. Taddese brings nearly 30 years of biopharma experience, including as President of Emerging Markets at Viatris where he ran an approximately $3 billion business, and more than 20 years at Pfizer spanning corporate finance and general management.
Key figures
- Board size after
- 9
- Board size before
- 8
- Annual director equity grant value
- $300,000
- Initial director equity award value
- $450,000
- Viatris emerging markets business size
- $3 billion
- Pfizer innovative pharma na business size
- $8 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.